Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.

• Revenue in USD (TTM)7.47k
• Net income in USD-19.52m
• Incorporated1996
• Employees5.00

• Location
  Oragenics Inc1990 MAIN STREET, SUITE 750SARASOTA 34236United StatesUSA
• Phone+1 (813) 286-7900
• Fax+1 (813) 286-7904
• Websitehttps://www.oragenics.com/